Search Results for

Showing 1 - 1 of 1 results
  1. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

Website Status

We are currently experiencing technical difficulties with our website. The login is not working. We are working on resolving this problem as quickly as possible and apologize for any inconvenience this may cause. If you need assistance please email